STAT

As states target high drug prices, pharma targets state lawmakers

The task of reining in drug prices is increasingly moving to the states — and so is pharma lobbying muscle.

It was expected to be a perfunctory statehouse meeting — three lobbyists and a legislator discussing a proposal to educate Louisiana doctors about the price of drugs they prescribe.

The bill seemed like a no-brainer in a country where even decades-old medicines can cost thousands and consumers are urged to make smart choices in buying health care. The legislation simply required pharmaceutical sales reps promoting medicines at doctors’ offices to also reveal a price.

No one expected the industry scrum that materialized.

About 10 pharma lobbyists flooded the room in Baton Rouge’s art deco state Capitol, some of them hired guns — lobbyists who’d never represented drug companies before, remembers Jeff Drozda, an insurance lobbyist at the 2016 meeting.

“The message was: We’re going to bring everything at you against these bills,” he said.

You're reading a preview, sign up to read more.

More from STAT

STAT4 min read
How The Drug Industry Keeps Winning In Washington
D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox. What if I told you the Sen. Thom Tillis campaign account was graced with nearly $20,000 in personal donations f
STAT5 min read
In A Small Study, A Cancer Vaccine Assist Beats Immunotherapy Drugs Alone
The largest study to date of a "cancer vaccine" found that combining it with an immunotherapy drug kept patients’ tumors in check longer, on average, than the drug alone.
STAT4 min readScience
HIV’s Genetic Code, Extracted From A Nub Of Tissue, Adds To Evidence Of Virus’ Emergence In Humans A Century Ago
In a nub of issue from the 1960s, scientists have found more clues of HIV’s emergence in humans.